


SciVision Biotech Inc.

*The Leading Technology
of Hyaluronic Acid ~*



Dr. Chun-Chang Chen



DISCLAIMER

SciVision's presentation contains our business operation, finance and sales prognosis which is derived from our existing internal / external data analysis. The future business scheme in this release reflect the current belief of SciVision as of the date of this release, we undertake no obligation to update these forward-looking statements for new information, future events, or otherwise.

Agenda

- 1. Company & Product Overview**
- 2. Business Operation**
- 3. Strategy & Prospect**



Company Profile

- Established : 12 November 2001
- Paid-in Capital : NT\$535 Million
- Industry : Hyaluronic acid-based medical device
- Main Products : Hyaluronic acid-based dermal filler
Hyaluronic acid-based viscosupplementation
Hyaluronic acid-based absorbable adhesion barrier
- Chairman : Mr. Kai-Chen Han
- Address : 9, South 6th Rd., K.E.P.Z., Kaohsiung 806, Taiwan, R.O.C.
1, South 1th Rd., K.E.P.Z., Kaohsiung 806, Taiwan, R.O.C. (New Factory)

SciVision Snapshot

- Biotechnology Company
- GMP certificate
- ISO13485
- Dermal filler approved by TFDA 、 CE and CFDA
- Viscosupplement approved by TFDA and CE
- TIPS



Grants

Obtain Seven SBIR Projects and so on, up to NT\$60M grants from Taiwan Government as the recognition of our outstanding research achievement.



Awards

Five National Industry Innovation Awards from Taiwan Government as the recognition of our outstanding R&D achievement.



Canada



Korea



ISO 9001



ISO 13485

Quality Assurance Certificates



Taiwan


Certificate Awards- Dermal Filler




Taiwan



EU



China



Korea



France



India



Colombia



Malaysia

Product Awards – Viscosupplementation



Taiwan



EU



France



Jordan



India



Philippines



Myanmar



Greece




Saudi Arabia


Core Technology

(Crosslinked Hyaluronic Acid Platform, CHAP®)

Strong worldwide IP protection for CHAP - Taiwan, China, Japan and USA



Patents



Taiwan



China



Japan



USA


EU patent is under review.

Product Overview – Dermal Filler

HA Dermal Filler



Dermal fillers help to diminish facial lines and restore volume and fullness in the face



- 1. Global market value up to US\$1.2 billion in 2015**
- 2. CAGR:12%**

Source : GlobalData



Product Advantages



HYADERMIS/ FACILLE

1. We offer a full range of dermal fillers, that meet various individual needs and specific requirements for facial aesthetic enhancements. There are reports to show long-lasting results.
2. Provide supreme quality with competitive prices, aiming to enlarge market share.
3. Channeling existing brands via Galderma's platforms and further growing rapidly up in the global market.




400,000+ Syringes used worldwide
Accounts coverage : 300+ aesthetics clinics in Taiwan

Healthcare - Viscosupplementation

HA Viscosupplementation




The products are indicated for the treatment of degenerative osteoarthritis via intra-articular injection to help minimize joint pains and improve joint mobility.



1. Global HA viscosupplementation market up to US\$2.3 billion in 2015
2. CAGR:7.5%

Source : GlobalData



Product Advantages



HVAJOINT/ HYVISC

1. Treatment: up to 6 months pain relief and fewer visits to physicians
2. Price: more cost-effective



3 million+ syringes used worldwide

Accounts coverage : 450+ clinics & 17 hospitals in Taiwan

Account for 50%+ market share in Taiwan

Involving Surgery - Absorbable Adhesion Barrier


Absorbable Adhesion Barrier



The hyaluronic acid-based gel for the prevention of postsurgical adhesions.

This product has larger Chinese market because of higher rate of caesarean section.

Anti-Adhesion Products Market, Global



1. Global market value up to US\$2.1 billion in 2015
2. CAGR : 8.9%

Source : GlobalData

Product Advantages

PROTAHERE Absorbable Adhesion Barrier

This product, a good viscosity, fluidity and high degree of biocompatibility of the gel, can be attached completely to the surface of the tissue and form a barrier, not move with the patient's movements. It can form an effective layer to reduce the probability of post-operative adhesion.



Gel-type is more user-friendly compared with membrane-type


Agenda

1. Company & Product Overview

2. Business Operation

3. Strategy & Prospect


Sales breakdown by geography



■ Taiwan ■ Asia ■ Europe/America

Sales breakdown by product

- Year 2014~2015 & 2016/1~11



■ Dermal filler ■ Viscosupplement ■ Other

Partnering with the Leading International Brand-Nestle

SciVision & Nestle signed an Exclusive Distribution Agreement to Collaborate in China for FACILLE Dermal Filler Distribution.

The most valuable brands of 2015

| Rank | Brand | Age | Country |
|------|---------------|-----|-------------|
| 1 | Google | 17 | USA |
| 2 | Apple | 39 | USA |
| 3 | Amazon | 20 | USA |
| 4 | GE | 123 | USA |
| 5 | Samsung | 77 | South Korea |
| 6 | Walmart | 53 | USA |
| 7 | Nike | 43 | USA |
| 8 | Mercedes-Benz | 115 | Germany |
| 9 | Facebook | 11 | USA |
| 10 | Nestle | 148 | Switzerland |

Galderma, Nestle’s subsidiary, an international dermatology company, is dedicated to innovating skin disease solutions & aesthetic & corrective products.


Its extensive product portfolio is available in 80 countries.

Its product, Restylane, has No.1 distribution network in China.

Agenda

1. Company & Product Overview
2. Business Operation
- 3. Strategy & Prospect**

Business Strategy



Technology focus in Taiwan and forward to Global

Advantages & Opportunity

Advantages

1. In-house Know-How
2. Worldwide Patents of **CHAP**
3. Good Quality

Opportunity

1. Soaring demands for aesthetics, healthcare, and surgical operation market in global.
2. Follow with Nestle's cooperation, alliances among international brands with different products.

Expanding to Meet Growing Demand

- The new factory will cover a total floor space of approximately 19,781.85 m²
- The new plant and facilities are designed to meet the requirements by cGMP, GEP, GAMP, ISPE, US FDA, and PIC/s GMP.
- Annual capacity of medical devices is 12M pre-filled syringes.
- Annual capacity for CMO is 23M pre-filled syringes.



**Building layout drawing
in 2014**



**Actual picture
in 2016**

Contract Manufacture Organization (CMO)

**Contract Manufacture Organization
(CMO)**

Manufacturing services offered, with volume capabilities ranging from small amount for preclinical R&D to larger volume necessary for clinical trial purposes and commercialization



1. Global market value up to US\$50.1 billion in 2015
2. CAGR : 12%

Source : BusinessInsights

Short-term and Long-term Plans

Short-term Plans :

1. Alliances with Nestle for global dermal filler market
2. New plant launch for operation
3. Absorbable Adhesion Barrier approved by TFDA and CFDA
4. Single-injection viscosupplement approved by US FDA
5. Branch out into CMO business

Long-term Plans :

1. Single-injection viscosupplement approved by CFDA
2. Other technology cross-link developed with hyaluronic acid
3. No.1 medical device contract manufacturer in Asia



Vision & Prospect

Vision

Science Creates Better Visions

Prospect

Leading HA brand in the world

The best choice in global market

Thank You



SciVISION
BIOTECH INC.